Alejandro Delvalle, DO
Internal Medicine · Miami Beach, FLNPI 1720080609
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,113 of the $11,613 with a category attached, or 87.1%. It is spread thinly across 39 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,460 and has fallen 60.3% since, to $1,372 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $32.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Melinta Therapeutics, LLC$2K
- Novo Nordisk$1K
- Pfizer$1K
- Johnson & Johnson$830
- Amarin Pharma, Inc.$550
- plus $4K from 33 others
What the payments were for
- Speaking & faculty fees$1,50013%
- Food & beverage$10,11387%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 94 | $2,306 |
| Melinta Therapeutics, LLC | 3 | $1,743 |
| Novo Nordisk | 44 | $1,386 |
| Pfizer | 42 | $1,076 |
| Johnson & Johnson | 30 | $830 |
| Amarin Pharma, Inc. | 26 | $550 |
| E.r. Squibb & Sons, L.L.C. | 13 | $435 |
| Lilly USA, LLC | 24 | $413 |
| Viiv Healthcare Company | 10 | $358 |
| Gilead | 7 | $322 |
| Abbott | 2 | $192 |
| Idorsia Pharmaceuticals US Inc | 8 | $169 |
| Saluda Medical Americas, Inc. | 2 | $153 |
| Actelion Pharmaceuticals US, Inc. | 1 | $148 |
| Amgen(2 entities) | 7 | $147 |
| Biosense Webster, Inc. | 1 | $125 |
| Nalu Medical, Inc. | 1 | $124 |
| Medtronic | 1 | $123 |
| Boehringer Ingelheim | 6 | $118 |
| Insmed, Inc. | 5 | $98 |
| Bayer | 3 | $84 |
| AstraZeneca(2 entities) | 3 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $70 |
| Astellas Pharma US Inc | 3 | $66 |
| Portola Pharmaceuticals, LLC | 2 | $65 |
| Sumitomo Pharma America, Inc. | 2 | $54 |
| Mallinckrodt Hospital Products Inc. | 2 | $54 |
| Novartis | 2 | $48 |
| Eisai Inc. | 2 | $39 |
| Redhill Biopharma Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| GSK | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| IBSA Pharma Inc. | 1 | $20 |
| Merck | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,613 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $57,448 |
| EliquisApixaban | 35 | $42,351 |
| MounjaroTirzepatide | 29 | $28,969 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $25,260 |
| FarxigaDapagliflozin Propanediol | 15 | $22,770 |
| Rosuvastatin Calcium | 108 | $1,872 |
| Omega-3 Acid Ethyl Esters | 21 | $1,292 |
| Nebivolol Hcl | 23 | $1,137 |
| Eszopiclone | 12 | $998 |
| Pantoprazole Sodium | 39 | $987 |
| Tamsulosin Hcl | 46 | $724 |
| Amlodipine Besylate | 83 | $718 |
| Omeprazole | 28 | $700 |
| Atorvastatin Calcium | 60 | $564 |
| Losartan Potassium | 31 | $439 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,386 | $57,44851 claims |
| PfizerEliquis | $1,076 | $42,35135 claims |
| Lilly USA, LLCMounjaro | $413 | $28,96929 claims |
| MerckJanumet | $20 | $25,26017 claims |
| AstraZenecaFarxiga | $72 | $22,77015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami Beach
- Jason ShapiroMiami Beach$69K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.